Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials

CONTEXT: Hepatitis C virus (HCV) infection is a major cause of liver-morbidity and mortality among patients with thalassemia. Peginterferon plus ribavirin is currently the recommended therapy for hepatitis C infection in patients do not have thalassemia, but using ribavirin in patients with thalasse...

Descripción completa

Detalles Bibliográficos
Autores principales: Aminizadeh, Ehsan, Alavian, Seyed Moayyed, Akbari Sari, Ali, Ebrahimi Daryani, Nasser, Behnava, Bita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876663/
https://www.ncbi.nlm.nih.gov/pubmed/27226796
http://dx.doi.org/10.5812/hepatmon.28537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876663/
https://www.ncbi.nlm.nih.gov/pubmed/27226796
http://dx.doi.org/10.5812/hepatmon.28537

Ejemplares similares